FMP
IDEAYA Biosciences, Inc.
IDYA
NASDAQ
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
23.14 USD
-0.01 (-0.04322%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
132.51M
170.36M
310.02M
363.14M
414.29M
561.12M
760M
1.03B
1.39B
1.89B
-34.25M
-25.23M
-62.35M
-40.7M
-16.17M
-85.16M
-115.34M
-156.22M
-211.58M
-286.57M
-3.31M
-2.37M
-3.62M
-7.23M
-12.48M
-11.29M
-15.29M
-20.71M
-28.05M
-37.99M
-37.56M
-27.6M
-65.97M
-47.93M
-28.65M
-96.45M
-130.63M
-176.93M
-239.63M
-324.56M
10.9
10.9
10.9
10.9
10.9
-86.97M
-106.22M
-129.73M
-158.44M
-193.51M
-674.87M